885274-77-1 Usage
Uses
Used in Pharmaceutical Research and Development:
PIPERIDINE-4-CARBOXYLIC ACID 4-CHLORO-BENZYLAMIDE is used as a chemical intermediate for the synthesis of new drugs and pharmaceutical formulations. Its distinctive structure and properties make it a promising candidate for the development of innovative therapeutic agents.
Used in Chemical Research:
In the field of chemical research, PIPERIDINE-4-CARBOXYLIC ACID 4-CHLORO-BENZYLAMIDE is utilized as a building block for the creation of diverse organic compounds. Its presence can contribute to the advancement of chemical libraries and the discovery of new chemical entities with potential applications across various industries.
It is crucial to handle PIPERIDINE-4-CARBOXYLIC ACID 4-CHLORO-BENZYLAMIDE with care, adhering to safety protocols and guidelines to mitigate any potential risks associated with its use.
Check Digit Verification of cas no
The CAS Registry Mumber 885274-77-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,8,5,2,7 and 4 respectively; the second part has 2 digits, 7 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 885274-77:
(8*8)+(7*8)+(6*5)+(5*2)+(4*7)+(3*4)+(2*7)+(1*7)=221
221 % 10 = 1
So 885274-77-1 is a valid CAS Registry Number.
885274-77-1Relevant academic research and scientific papers
Design, synthesis, and biological evaluation of novel piperidine-4- carboxamide derivatives as potent CCR5 inhibitors
Hu, Suwen,Gu, Quan,Wang, Zhilong,Weng, Zhiyong,Cai, Yunrui,Dong, Xiaowu,Hu, Yongzhou,Liu, Tao,Xie, Xin
, p. 259 - 266 (2014/01/06)
Based on a putative 'Y shape' pharmacophore model of CCR5 inhibitors, a series of novel piperidine-4-carboxamide derivatives were designed and synthesized using a group-reverse strategy. Among synthesized target compounds, 16g (IC50 = 25.73 nM) and 16i (IC50 = 25.53 nM) showed equivalent inhibitory activity against CCR5 to that of the positive control maraviroc (IC50 = 25.43 nM) in calcium mobilization assay. Selected compounds were further tested for their antiviral activity in HIV-1 single cycle assay. Two compounds, 16g and 16i, displayed antiviral activity with IC 50 values of 73.01 nM and 94.10 nM, respectively. Additionally, the pharmacokinetic properties and inhibitory potency against hERG of 16g were evaluated, providing a foundation for ongoing optimization.
